CA2811285A1 - Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia - Google Patents

Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia Download PDF

Info

Publication number
CA2811285A1
CA2811285A1 CA2811285A CA2811285A CA2811285A1 CA 2811285 A1 CA2811285 A1 CA 2811285A1 CA 2811285 A CA2811285 A CA 2811285A CA 2811285 A CA2811285 A CA 2811285A CA 2811285 A1 CA2811285 A1 CA 2811285A1
Authority
CA
Canada
Prior art keywords
dose
morphine
oxycodone hydrochloride
morphine sulfate
subsequent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2811285A
Other languages
English (en)
French (fr)
Inventor
Patricia T. Richards
Warren C. Stern
Laurel J. Mengle-Gaw
Benjamin D. Schwartz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QRxPharma Ltd
Original Assignee
QRxPharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/881,677 external-priority patent/US7923453B1/en
Priority claimed from US12/881,728 external-priority patent/US8012990B2/en
Priority claimed from US13/185,016 external-priority patent/US8222267B2/en
Application filed by QRxPharma Ltd filed Critical QRxPharma Ltd
Publication of CA2811285A1 publication Critical patent/CA2811285A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2811285A 2010-09-14 2011-09-14 Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia Abandoned CA2811285A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12/881,677 2010-09-14
US12/881,677 US7923453B1 (en) 2009-10-14 2010-09-14 Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
US12/881,728 2010-09-14
US12/881,728 US8012990B2 (en) 2009-10-14 2010-09-14 Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
US13/185,016 2011-07-18
US13/185,016 US8222267B2 (en) 2009-10-14 2011-07-18 Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
PCT/US2011/051577 WO2012037239A1 (en) 2010-09-14 2011-09-14 Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia

Publications (1)

Publication Number Publication Date
CA2811285A1 true CA2811285A1 (en) 2012-03-22

Family

ID=44903337

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2811285A Abandoned CA2811285A1 (en) 2010-09-14 2011-09-14 Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia

Country Status (7)

Country Link
EP (1) EP2616075A1 (enrdf_load_stackoverflow)
JP (1) JP2013537232A (enrdf_load_stackoverflow)
CN (1) CN103415291A (enrdf_load_stackoverflow)
AU (1) AU2011302137A1 (enrdf_load_stackoverflow)
CA (1) CA2811285A1 (enrdf_load_stackoverflow)
WO (1) WO2012037239A1 (enrdf_load_stackoverflow)
ZA (1) ZA201302585B (enrdf_load_stackoverflow)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US20050053659A1 (en) 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
AU2009203070A1 (en) * 2008-05-20 2009-12-10 Qrxpharma Limited Dual opioid pain therapy
US7923453B1 (en) * 2009-10-14 2011-04-12 QRxPharma Ltd. Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
US8012990B2 (en) * 2009-10-14 2011-09-06 QRxPharma Ltd. Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
US20170123700A1 (en) 2015-11-03 2017-05-04 Samsung Electronics Co., Ltd. Io redirection methods with cost estimation

Also Published As

Publication number Publication date
EP2616075A1 (en) 2013-07-24
CN103415291A (zh) 2013-11-27
WO2012037239A1 (en) 2012-03-22
AU2011302137A1 (en) 2013-05-02
JP2013537232A (ja) 2013-09-30
ZA201302585B (en) 2014-05-28

Similar Documents

Publication Publication Date Title
AU2006217870B2 (en) Dosage form containing oxycodone and naloxone
Schmidt Alvimopan (ADL 8-2698) is a novel peripheral opioid antagonist
CA2800094C (en) Liquid nasal spray containing low-dose naltrexone
US20090298862A1 (en) Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition
EP2632442A2 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
US7923453B1 (en) Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
US8012990B2 (en) Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
CA2811285A1 (en) Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
US8222267B2 (en) Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
Ferro et al. Management of pain in renal failure
Chen et al. Methylnaltrexone bromide
AU2011254554B2 (en) Liquid nasal spray containing low-dose naltrexone
US20120283283A1 (en) Methods for detecting enhanced risk of opioid-induced hypoxia in a patient
Partownavid Morphine sulfate controlled-release
AU2017213491A1 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20160914